This page shows the latest Biktarvy news and features for those working in and with pharma, biotech and healthcare.
After changing to Biktarvy, 98% of patients in two groups were suppressed at week 48. ... After switching to Biktarvy, 98% of participants in both cohorts 1 and 2 remained suppressed at week 48.
Gilead Sciences (Gilead) has announced the latest results from its two phase 3 studies assessing the long-term safety and efficacy profile of Biktarvy for the treatment of people living with ... These outcomes were reported in participants 96 weeks after
Biktarvy is a complete HIV treatment, combining three medicines to form the smallest three-drug, single-tablet regimen (STR) available, as a simple once-daily dosing regimen. ... This bolsters the efficacy and tolerability profile of Biktarvy as a
The drop was also partially offset by a 20% increase to $2.3bn from Biktarvy (bictegravir/emtricitabine/tenofovir) and Trodelvy (sacituzumab govitecan-hziy), said Gilead. ... The dynamics of the HIV treatment market further improved and this contributed
Overall, HIV product sales decreased by 12% to $3.7bn for the first quarter, although sales of its newer HIV treatment Biktarvy increased by 8% year-on-year in Q1.
Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) product.
More from news
Approximately 7 fully matching, plus 18 partially matching documents found.
No results were found
PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...